STRYKER CORP(SYK)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
STRYKER CORP (SYK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SYK at 72.1/100 on a 32-signal composite quality model, placing it at rank #158 of 2,960 stocks — the top 10% of the AI-ranked universe. SYK scores in the top quartile across revenue scale (94.2), balance sheet strength (80.5). Based on the latest XBRL financial filings (Q2 2026), STRYKER CORP reports quarterly revenue of $6.6B, net income of $1.3B, an operating margin of 25.2%. Top institutional holders of SYK by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, JPMORGAN CHASE, based on the most recent SEC filings. SYK trades on the NYSE exchange and files with the SEC under CIK 310764. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SYK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STRYKER CORP directly from SEC EDGAR.
AI Quality Score
72.1/100
AI Rank
#158
Revenue
$6.6B
Net Income
$1.3B
Free Cash Flow
$1.1B
Operating Margin
25.2%
SYK key financials by period
STRYKER CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$25.1B
$3.2B
19.5%
FY 2024
10-K
$22.6B
$3.0B
16.3%
FY 2023
10-K
$20.5B
$3.2B
19.0%
FY 2022
10-K
$18.4B
$2.4B
15.4%
FY 2021
10-K
$17.1B
$2.0B
15.1%
FY 2020
10-K
$14.4B
$1.6B
15.5%
Institutions holding SYK
Institutional investors reporting a position in STRYKER CORP on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-31 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net sales rose 9.4% to $6,589M while a $158M reversal of 2025 tariffs helped lift gross margin to 68.3% and operating margin to 25.2%.
Biggest Revenue Drivers
MedSurg and Neurotechnology$3,625M+9.7% YoY
Up 9.2% in constant currency, 9.1% from unit volume and 0.1% from higher prices across most businesses
Orthopaedics$2,964M+9.1% YoY
Constant currency up 8.7%; excluding acquisitions/divestitures up 8.6% from higher shipments across all Orthopaedics businesses
Biggest Revenue Drivers
Total revenue: $6.6B+9.4% YoY
MedSurg and Neurotechnology$3,625M+9.7% YoY
Up 9.2% in constant currency, 9.1% from unit volume and 0.1% from higher prices across most businesses
Within MedSurg and Neurotechnology
Medical$1,122M+13.4% YoY
United States sales up 12.6%, international up 17.9%
Vascular$496M-0.7% YoY
Down 1.8% in constant currency, with United States sales down 6.7%
Orthopaedics$2,964M+9.1% YoY
Constant currency up 8.7%; excluding acquisitions/divestitures up 8.6% from higher shipments across all Orthopaedics businesses
Within Orthopaedics
Trauma and Extremities$1,072M+11.9% YoY
United States sales up 12.5%, international up 10.3%
Largest Expense Items
Selling, general and administrative$2,229M+7.2% YoY
Fell to 33.8% of sales from 34.5% on spend discipline and lower acquisition and integration-related charges, offset by structural optimization charges
Cost of sales$2,091M-4.1% YoY
Benefited from reduction of certain import tariffs and lower amortization of inventory stepped up to fair value
Research, development and engineering$434M+6.6% YoY
6.6% of net sales, relatively flat with 6.8% in 2025
Amortization of intangible assets$175M-6.4% YoY
Margins: Gross margin rose to 68.3% from 63.8%, driven by a reversal of 2025 tariffs (260 bps) and lower inventory step-up amortization (110 bps). Operating margin reached 25.2% versus 18.5%.
Watch Items from the Filing
A $158M reversal of 2025 tariffs added 260 bps to gross margin and $0.34 to diluted EPS; management excludes it from adjusted results.
Vascular sales fell 0.7% to $496M (-1.8% constant currency), with United States Vascular down 6.7% — the only declining business.
Cybersecurity incident first reported March 11, 2026 caused idle production time raising manufacturing costs; forward-looking statements cite continuing uncertainty on operations and results.
Structural optimization and other special charges rose to $95M from $11M, including $70M of 'other charges' in the quarter.
Level 3 contingent consideration grew to $756M from $518M, including $271M from the AVS acquisition with up to $400M future milestones.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
